The Indian pharmaceutical industry enjoys certain advantages, including low costs of innovation and capital expenditure, and strong domestic support for manufacturing, from raw material requirements to finished products . The competitive structure of the pharmaceutical industry was being redefined due to the threat of new competitors, intense price competition, the entry of large players, new regulations and rules, and a shift in focus. Additionally, partnerships between pharmaceutical and biotechnology companies were growing rapidly. The global pharmaceutical market is undergoing a rapid transformation. There has been a dramatic shift towards emerging markets as Western markets slowed. In terms of economic environment, although India was characterized by low gross domestic product per capita and Indian drug prices were among the lowest in the world, under the leadership of Dr. Monahan Singh, the country began the process of liberalization. This economic reform, along with the globalization trend, was shifting the economy from import substitution to an export-led economy. Improvements to infrastructure, distribution and logistics were aimed at attracting foreign direct investment, encouraged by raising the maximum foreign ownership limit to 51% in the sector. At the same time, increasing pressure from shareholders has caused industry consolidation: further mergers and acquisitions will take place in the coming years. Even though there was a growing middle class with high market potential; poverty continued to be a significant problem. Achieving profitability has not been easy for the company as the Indian government has imposed tariffs on imports and other regulatory issues. The political and legal environment...... middle of paper...... costs. Update to the PresentBased on our research into what happened to the company with the issues of the case, we found that on July 5 Eli Lilly announced that it had purchased ownership stakes in Ranbaxy for $17 million which includes the brand name and the actions. Today, Eli Lilly continues to develop and implement campaigns such as the "Lilly Global Health Innovation Campaign" in an effort to help local governments reduce the expansion of diabetes and multidrug-resistant tuberculosis (MDR-TB) among the population , closely monitoring data collection by members and sharing it with local agencies globally. The company has partnered with Indian companies to launch generic drugs in India. Eli Lilly continues to innovate and improve insulin products and mechanisms. They recently collaborated with Boehringer Ingelheim in India and launched a new insulin product.